# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000899923-24-000018
Filing Date
2024-02-28
Accepted
2024-02-28 08:31:31
Documents
174
Period of Report
2023-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | mygn-20231231.htm iXBRL | 10-K | 2177961
2 | EX-10.1 | phasei_leaseterminationagr.htm | EX-10.1 | 31029
3 | EX-10.2 | phaseii_leaseterminationag.htm | EX-10.2 | 29349
4 | EX-10.3 | phaseiii_leaseterminationa.htm | EX-10.3 | 29594
5 | EX-10.4 | leasedrawbridge_myriadgene.htm | EX-10.4 | 716665
6 | EX-10.5 | healthpeak233egrand-leaseb.htm | EX-10.5 | 915389
7 | EX-10.16 | severanceandchangeofcontro.htm | EX-10.16 | 75308
8 | EX-10.17 | executiveemploymentagreeme.htm | EX-10.17 | 68706
9 | EX-10.18 | riggsbee_separationandcons.htm | EX-10.18 | 85679
10 | EX-10.19 | lambert_separationandconsu.htm | EX-10.19 | 82041
11 | EX-21.1 | mygn-20231231ex211.htm | EX-21.1 | 16398
12 | EX-23.1 | mygn-20231231xexx231.htm | EX-23.1 | 5769
13 | EX-31.1 | mygn-20231231xexx311.htm | EX-31.1 | 9672
14 | EX-31.2 | mygn-20231231xexx312.htm | EX-31.2 | 9670
15 | EX-32 | mygn-20231231xexx32.htm | EX-32 | 5252
16 | EX-97.1 | myriadclawbackpolicy-exx971.htm | EX-97.1 | 32198
22 |  | image_01.jpg | GRAPHIC | 390209
23 |  | image_0a.jpg | GRAPHIC | 123354
24 |  | image_0b.jpg | GRAPHIC | 234321
25 |  | image_1.jpg | GRAPHIC | 255051
26 |  | image_10.jpg | GRAPHIC | 1863
27 |  | image_101.jpg | GRAPHIC | 95179
28 |  | image_110.jpg | GRAPHIC | 1421773
29 |  | image_111.jpg | GRAPHIC | 91056
30 |  | image_121.jpg | GRAPHIC | 390237
31 |  | image_12a.jpg | GRAPHIC | 1800
32 |  | image_13.jpg | GRAPHIC | 1792
33 |  | image_131.jpg | GRAPHIC | 92023
34 |  | image_141.jpg | GRAPHIC | 822460
35 |  | image_151.jpg | GRAPHIC | 8332792
36 |  | image_161.jpg | GRAPHIC | 6803
37 |  | image_17.jpg | GRAPHIC | 1718
38 |  | image_18.jpg | GRAPHIC | 1719
39 |  | image_2.jpg | GRAPHIC | 516230
40 |  | image_20.jpg | GRAPHIC | 1751
41 |  | image_210.jpg | GRAPHIC | 194943
42 |  | image_26.jpg | GRAPHIC | 1309
43 |  | image_27.jpg | GRAPHIC | 1344
44 |  | image_28.jpg | GRAPHIC | 1365
45 |  | image_29.jpg | GRAPHIC | 718
46 |  | image_3.jpg | GRAPHIC | 622026
47 |  | image_31.jpg | GRAPHIC | 1489
48 |  | image_32.jpg | GRAPHIC | 1358
49 |  | image_33.jpg | GRAPHIC | 6712
50 |  | image_34.jpg | GRAPHIC | 7071
51 |  | image_35.jpg | GRAPHIC | 725771
52 |  | image_4.jpg | GRAPHIC | 722208
53 |  | image_41.jpg | GRAPHIC | 533973
54 |  | image_5.jpg | GRAPHIC | 725724
55 |  | image_51.jpg | GRAPHIC | 290699
56 |  | image_6.jpg | GRAPHIC | 357367
57 |  | image_61.jpg | GRAPHIC | 241012
58 |  | image_7.jpg | GRAPHIC | 1580
59 |  | image_71.jpg | GRAPHIC | 94354
60 |  | image_8.jpg | GRAPHIC | 1617
61 |  | image_81.jpg | GRAPHIC | 96694
62 |  | image_9.jpg | GRAPHIC | 880
63 |  | image_91.jpg | GRAPHIC | 1592714
64 |  | mygn-20231231_g1.jpg | GRAPHIC | 28910
| Complete submission text file | 0000899923-24-000018.txt |  | 40852619

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
17 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | mygn-20231231.xsd | EX-101.SCH | 80355
18 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | mygn-20231231_cal.xml | EX-101.CAL | 138364
19 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | mygn-20231231_def.xml | EX-101.DEF | 359672
20 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | mygn-20231231_lab.xml | EX-101.LAB | 1110614
21 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | mygn-20231231_pre.xml | EX-101.PRE | 718659
176 | EXTRACTED XBRL INSTANCE DOCUMENT | mygn-20231231_htm.xml | XML | 1947976

Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-26642 | Film No.: 24690418
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)